期刊文献+

丙戊酸钠对拉莫三嗪在大鼠体内药代动力学影响 被引量:1

The pharmacokinetics effect of Valproate on Lamotrigine in rats
在线阅读 下载PDF
导出
摘要 目的探讨丙戊酸钠对拉莫三嗪在大鼠体内的药代动力学影响。方法将16只健康大鼠随机分为单药组(30.0mg/kg拉莫三嗪)和联合用药组(50.0mg/kg丙戊酸钠+30mg/kg拉莫三嗪),单药组和联合用药组分别灌胃空白溶剂和丙戊酸钠7d,每天1次。第8d两组均给予拉莫三嗪灌胃,给药后不同时间点采血,HPLC-MS法测定大鼠体内拉莫三嗪血药浓度,比较两组间主要的药代动力学参数。结果与单药组比较,联用组拉莫三嗪主要药代动力学参数Cmax、AUC0-t等参数值显著上升,组间比较差异具有统计学意义(P<0.05)。结论联合应用丙戊酸钠可影响大鼠体内拉莫三嗪的药代动力学特性,与其它相关研究结论基本一致。 Objective To study the pharmacokinetics effect of Valproate on Lamotrigine in rats. Methods 16 healthy rats were randomly divided into single drug group(30mg/kg lamotrigine) and combination group(50mg/kg valproate and 30mg/kg lamotrigine),single drug group and combined treatment group were given intragastric administration of blank solvent and valproate for7 days once a day,on the eighth day the two groups were given intragastric administration of lamotrigine,administered at different time points after blood were measured in serum concentrations of lamotrigine in rats with HPLC-MS method,the main pharmacokinetic parameters between the two groups. Results compared with the single drug group,combination group lamotrigine the main pharmacokinetic parameters of Cmax. and AUC0-t increased significantly,the difference was statistically significant(P〈0.05).Conclusion The pharmacokinetic characteristics combined with valproate effects of lamotrigine in rats,and the conclusion and other related research is basically the same.
出处 《江西医药》 CAS 2017年第9期851-853,共3页 Jiangxi Medical Journal
关键词 丙戊酸钠 拉莫三嗪 药代动力学 高效液相色谱质谱联用 Valproate Lamotrigine Pharmacokinetics HPLC-MS
  • 相关文献

参考文献5

二级参考文献49

  • 1仇亚鹏.丙戊酸钠治疗小儿癫痫[J].四川医学,2006,27(6):643-644. 被引量:4
  • 2周青,余江平,范渝蓉.反相高效液相色谱法测定卡马西平的血药浓度[J].中国药业,2007,16(14):27-28. 被引量:10
  • 3Anderson GD, Gidal BE, Messenheimer JA, et al. Time course of lamotrigine de induction: impact of step wise with- drawal of carbamazepine or phenytoin [J]. Epilepsy Res, 2002, 49 (3): 211-217.
  • 4Zhang S, Wang I., Lu W. Population pharmacokinetics of lam- otrigine in Chinese children with epilepsy [J]. Zhongguo Dang Dai Er Ke Za Zhi, 2008, 10 (2): 105-109.
  • 5Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic in- teraction o levetiracetam on carbamazepine, valproic acid, topiranmte, and lamotrigine in children with epilepsy [J]. Epi- lepsia, 2007, 48 (11): 2111-2115.
  • 6Rivas N, Buelga DS, Elger CE, et al. Population pharmacoki- netics of lamotrigine with data from therapeutic drug monito- ring in German and Spanish patients with epilepsy [J] Ther DrugMonit, 2008, 30 (4): 483 489.
  • 7Punyawudho B, Ramsay RE, Macias FM, et al. Population pharmacokinetics of lamotrigine in elderly patients [J]. J Clin Pharmacol, 2008, 48 (4): 455 463.
  • 8Milovanovic JR, Jankovic SM. Population pharmacokinetics of lamotrigine in patients with epilepsy [J]. Int J Clin Pharmacol Ther, 2009, 47 (12): 752-760.
  • 9Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady state pharmaeokinetics of earbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiaga- bine [J]. Epilepsia, 2011, 52 (2): 405-409.
  • 10Rowland A, Elliot DJ, Williams JA, et al. In vitro character ization of lamotrigine N2-glucuronidation and the lamotrigine- valproic acid interaction[J]. Drug Metab Dispos, 2006, 34 (6) : 1055-1062.

共引文献30

同被引文献3

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部